Keyphrases
Idiopathic Inflammatory Myopathies
87%
Myositis
87%
Confidence Interval
79%
Spain
65%
Tertiary Hospital
57%
Dermatomyositis
53%
Locally Advanced Cervical Cancer
44%
Healthcare Workers
44%
Polymyositis
38%
Influenza Vaccination
36%
Immunization
36%
Catalonia
35%
Barcelona
34%
Inflammatory Bowel Disease
33%
Pertussis
33%
Pregnant Women
33%
Autoantibodies
31%
Interstitial Lung Disease
30%
Vaccination
28%
Para-aortic Lymphadenectomy
28%
Influenza Vaccine
25%
Extraperitoneal
25%
Cancer Screening
22%
Infrarenal
22%
Cancer-associated Myositis
21%
Antisynthetase Autoantibodies
20%
Reactogenicity
20%
Epidemiological Characteristics
19%
Chickenpox
18%
Vaccination Coverage
18%
High Risk
18%
Measles-mumps-rubella Vaccine
18%
Infection Risk
18%
Hebron
17%
University Hospital
17%
Hospitalized Pediatric Patients
16%
Hepatitis B Vaccine
16%
Antikeratin Antibodies
16%
Obstetricians
16%
Pre-exposure Prophylaxis (PrEP)
16%
Varicella Vaccine
16%
Laparoscopic Staging
16%
Outside-in
16%
Influenza Vaccine Coverage
16%
Clinical Significance
16%
Thyroid Disease
16%
Egg Allergy
16%
Mumps Vaccine
16%
Vaccine Allergy
16%
Polymyositis-dermatomyositis
16%
Medicine and Dentistry
Myositis
100%
Diseases
83%
Autoantibodies
47%
Dermatomyositis
47%
Cervical Cancer
42%
Malignant Neoplasm
39%
Influenza Vaccination
39%
Influenza Vaccine
36%
Retroperitoneal Lymph Node Dissection
36%
Patient with Inflammatory Bowel Disease
33%
Health Care
29%
Infection
28%
Interstitial Lung Disease
26%
Polymyositis
23%
Diagnosis
22%
Cancer Screening
20%
Metastatic Carcinoma
20%
Reactogenicity
20%
COVID-19
19%
Disease Activity
18%
Pertussis
16%
Capillaroscopy
16%
Thyroid Disease
16%
Measles Mumps Vaccine
16%
Measles Rubella Vaccine
16%
Antisynthetase Syndrome
16%
Meta-Analysis
16%
Hyperlactatemia
16%
Systematic Review
16%
Carbapenem
16%
Occupational Exposure
16%
Hepatitis B Vaccine
16%
Chickenpox Vaccine
16%
Socioeconomic Status
16%
Calcineurin Inhibitor
16%
Clinical Significance
16%
Chickenpox
16%
Pediatrics Patient
16%
Capillary Microscopy
16%
Egg Allergy
16%
COVID-19 Vaccination
16%
Positron Emission Tomography-Computed Tomography
16%
Carbapenem Derivative
16%
Post-Exposure Prophylaxis
16%
Revaccination
16%
Hepatitis B Virus
16%
Immunogenicity
16%
Messenger RNA
16%
Laparoscopic Surgery
16%
Human Immunodeficiency Virus
12%
Pharmacology, Toxicology and Pharmaceutical Science
Myositis
49%
Autoantibodies
35%
Disease
34%
Influenza Vaccine
33%
Chickenpox
33%
Prevalence
30%
Dermatomyositis
24%
Interstitial Lung Disease
24%
Polymyositis
22%
Vaccine Acceptance
16%
Hepatitis B Vaccine
16%
Hospital Infection
16%
Stress Incontinence
16%
Infection
16%
Measles Mumps Vaccine
16%
Egg Allergy
16%
Measles Rubella Vaccine
16%
Inflammatory Bowel Disease
16%
Carbapenem Derivative
16%
Adverse Event
16%
Vaccine
16%
Calcineurin Inhibitor
16%
Messenger RNA
16%
Thyroid Disease
16%
Hyperlactatemia
16%
Chickenpox Vaccine
16%
Keratin Antibody
16%
Carbapenem
16%
Pertussis
16%
Measles
16%
Antisynthetase Syndrome
16%
Immunogenicity
16%
COVID-19 Vaccine
16%
Hepatitis B Virus
16%
Occupational Exposure
16%
Messenger RNA
16%
Infection
15%
HIV
12%
Cross-Sectional Study
11%
Virus Vaccine
11%
Adverse Event
9%
Prospective Cohort Study
9%
Tacrolimus
8%
Ciclosporin
8%
Prevalence
6%
Enzyme-Linked Immunosorbent Assay
6%
Postoperative Complication
5%
Urine Retention
5%
Comorbidity
5%
Hepatitis B Antigen
5%
